WO1998005769A3 - Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase - Google Patents

Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase Download PDF

Info

Publication number
WO1998005769A3
WO1998005769A3 PCT/CA1997/000540 CA9700540W WO9805769A3 WO 1998005769 A3 WO1998005769 A3 WO 1998005769A3 CA 9700540 W CA9700540 W CA 9700540W WO 9805769 A3 WO9805769 A3 WO 9805769A3
Authority
WO
WIPO (PCT)
Prior art keywords
ribonucleotide reductase
components
directed against
antisense sequences
sequences directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA1997/000540
Other languages
French (fr)
Other versions
WO1998005769A2 (en
Inventor
Jim A Wright
Aiping H Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genesense Technologies Inc
Original Assignee
Genesense Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE69734589T priority Critical patent/DE69734589T2/en
Application filed by Genesense Technologies Inc filed Critical Genesense Technologies Inc
Priority to CA002262776A priority patent/CA2262776C/en
Priority to EP97932690A priority patent/EP0917569B1/en
Priority to IL12812497A priority patent/IL128124A0/en
Priority to AT97932690T priority patent/ATE309345T1/en
Priority to AU36175/97A priority patent/AU738592C/en
Priority to NZ333802A priority patent/NZ333802A/en
Priority to JP50741098A priority patent/JP4301576B2/en
Publication of WO1998005769A2 publication Critical patent/WO1998005769A2/en
Publication of WO1998005769A3 publication Critical patent/WO1998005769A3/en
Priority to IL128124A priority patent/IL128124A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0093—Oxidoreductases (1.) acting on CH or CH2 groups (1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Compounds and methods for modulating cell proliferation, preferably inhibiting the proliferation of tumor cells are described. Compounds that may be used to modulate cell proliferation include inhibitors of ribonucleotide reductase expression, that is, inhibitors of transcription or translation of the gene encoding ribonucleotide reductase. Antisense oligonucleotides complementary to regions of ribonucleotide reductase gene are particularly useful inhibitors.
PCT/CA1997/000540 1996-08-02 1997-08-01 Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase Ceased WO1998005769A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP50741098A JP4301576B2 (en) 1996-08-02 1997-08-01 Anti-tumor antisense sequences directed against the R1 and R2 components of ribonucleotide reductase
CA002262776A CA2262776C (en) 1996-08-02 1997-08-01 Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
EP97932690A EP0917569B1 (en) 1996-08-02 1997-08-01 Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
IL12812497A IL128124A0 (en) 1996-08-02 1997-08-01 Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
AT97932690T ATE309345T1 (en) 1996-08-02 1997-08-01 ANTITUMOR ANTISENSE SEQUENCES AGAINST H1 AND R2 COMPOUNDS OF RIBONUCLEOTIDE REDUCTASE
DE69734589T DE69734589T2 (en) 1996-08-02 1997-08-01 Antitumor Antisense Sequences Against H1 and R2 Compounds of Ribonucleotide Reduction
NZ333802A NZ333802A (en) 1996-08-02 1997-08-01 Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
AU36175/97A AU738592C (en) 1996-08-02 1997-08-01 Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
IL128124A IL128124A (en) 1996-08-02 1999-01-19 Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2304096P 1996-08-02 1996-08-02
US60/023,040 1996-08-02
US3995997P 1997-03-07 1997-03-07
US60/039,959 1997-03-07

Publications (2)

Publication Number Publication Date
WO1998005769A2 WO1998005769A2 (en) 1998-02-12
WO1998005769A3 true WO1998005769A3 (en) 1998-06-25

Family

ID=26696655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1997/000540 Ceased WO1998005769A2 (en) 1996-08-02 1997-08-01 Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase

Country Status (12)

Country Link
US (1) US5998383A (en)
EP (1) EP0917569B1 (en)
JP (1) JP4301576B2 (en)
CN (1) CN1189562C (en)
AT (1) ATE309345T1 (en)
AU (1) AU738592C (en)
CA (1) CA2262776C (en)
DE (1) DE69734589T2 (en)
ES (1) ES2256893T3 (en)
IL (2) IL128124A0 (en)
NZ (1) NZ333802A (en)
WO (1) WO1998005769A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US7223849B1 (en) * 1996-07-01 2007-05-29 Genesense Technologies Inc. Oligonucleotides from the untranslated regions of housekeeping genes and methods of using same to modulate cell growth
US6593305B1 (en) 1996-08-02 2003-07-15 Genesense Technologies Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
EP0971731B1 (en) 1997-03-19 2004-05-12 GeneSense Technologies Inc. Suppression of malignancy utilizing ribonucleotide reductase r1
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
US6610539B1 (en) * 1997-07-10 2003-08-26 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
EP1584681A3 (en) * 1997-07-10 2005-11-09 GeneSense Technologies Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999049029A1 (en) * 1998-03-20 1999-09-30 Benitec Australia Ltd Control of gene expression
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
EP2314700A1 (en) * 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US6121000A (en) * 1999-02-11 2000-09-19 Genesense Technologies, Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
US20040138168A1 (en) * 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
US6642033B1 (en) 1999-07-20 2003-11-04 V.I. Technologies, Inc. Nucleic acids for detecting parvovirus and methods of using same
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
CN1301816A (en) * 1999-12-27 2001-07-04 上海博德基因开发有限公司 New polypeptide-nucleotide reductase 10 and polynucleotide codign such polypeptide
MXPA02009069A (en) * 2000-03-17 2004-04-05 Benitec Australia Ltd Genetic silencing.
EP1229134A3 (en) * 2001-01-31 2004-01-28 Nucleonics, Inc Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
DE10131148A1 (en) * 2001-06-28 2003-01-16 I P L Internat Pharmaceutics L Xenogenic oligo- and / or polyribonucleotides as agents for the treatment of malignant tumors
WO2004070033A1 (en) * 2003-02-10 2004-08-19 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
CA2524255C (en) * 2003-03-21 2014-02-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
CA2526393A1 (en) * 2003-05-21 2004-12-02 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r1 and uses thereof in the treatment of cancer
WO2004106518A1 (en) * 2003-05-31 2004-12-09 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
JP2007529199A (en) 2003-10-23 2007-10-25 イルミジェン バイオサイエンシーズ， インコーポレイテッド Detection of mutations in OAS1, a gene associated with resistance to viral infection
AU2005203822A1 (en) * 2004-01-12 2005-07-21 Lorus Therapeutics Inc. Antisense oligonucleotides directed to ribonucleotide reductase R2 and uses thereof in combination therapies for the treatment of cancer
US8029815B2 (en) * 2004-04-28 2011-10-04 Elford Howard L Methods for treating or preventing restenosis and other vascular proliferative disorders
CA2566519C (en) * 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
US7968762B2 (en) * 2004-07-13 2011-06-28 Van Andel Research Institute Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
CA2577036A1 (en) * 2004-08-18 2006-02-23 Genesense Technologies Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
US20060185027A1 (en) * 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
EP1866414B9 (en) * 2005-03-31 2012-10-03 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي PI-3 Kinase inhibitors and methods of their use
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
EP2030615A3 (en) * 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
US20100204305A1 (en) * 2007-12-11 2010-08-12 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
EP2240475B1 (en) 2007-12-20 2013-09-25 Novartis AG Thiazole derivatives used as pi 3 kinase inhibitors
WO2010027279A2 (en) * 2008-09-04 2010-03-11 Genesis Research And Development Corporation Limited Compositions and methods for the treatment and prevention of neoplastic disorders
EP2350264A4 (en) 2008-11-06 2012-08-29 Univ Johns Hopkins TREATMENT OF CHRONIC INFLAMMATORY RESPIRATORY DISEASES
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
AR082418A1 (en) 2010-08-02 2012-12-05 Novartis Ag CRYSTAL FORMS OF 1- (4-METHYL-5- [2- (2,2,2-TRIFLUORO-1,1-DIMETHYL-Ethyl) -PIRIDIN-4-IL] -TIAZOL-2-IL) -AMIDE OF 2 -AMIDA OF THE ACID (S) -PIRROLIDIN-1,2-DICARBOXILICO
EP2630240A1 (en) * 2010-10-18 2013-08-28 Arrowhead Research Corporation Compositions and methods for inhibiting expression of rrm2 genes
JP5963777B2 (en) 2011-01-31 2016-08-03 ノバルティス アーゲー New heterocyclic derivatives
CN104039790B (en) 2011-10-28 2016-04-13 诺华股份有限公司 Purine derivatives and their application in treating diseases
KR20150009540A (en) 2012-05-16 2015-01-26 노파르티스 아게 Dosage regimen for a pi-3 kinase inhibitor
SI3076969T1 (en) 2013-12-06 2021-12-31 Novartis Ag Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
US20180280370A1 (en) 2015-11-02 2018-10-04 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
EP0690869A1 (en) * 1993-03-23 1996-01-10 The Board Of Trustees Of The Leland Stanford Junior University Cellular regulation with riboregulators

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BARKER R H JR ET AL: "Inhibition of Plasmodium falciparum malaria using antisense oligodeoxynucleotides.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 93 (1). 1996. 514-518. ISSN: 0027-8424, XP002053162 *
BJÖRKLUND S ET AL: "S-PHASE-SPECIFIC EXPRESSION OF MAMMALIAN RIBONUCLEOTIDE REDUCTASE R1 AND R2 SUBUNIT MESSENGER RNAS.", BIOCHEMISTRY 29 (23). 1990. 5452-5458. CODEN: BICHAW ISSN: 0006-2960, XP002053156 *
CHAKRABARTI, DEBOPAM ET AL: "Cloning and characterization of subunit genes of ribonucleotide reductase, a cell-cycle-regulated enzyme, from Plasmodium falciparum", PROC. NATL. ACAD. SCI. U. S. A. (1993), 90(24), 12020-4 CODEN: PNASA6;ISSN: 0027-8424, 1993, XP002053163 *
HUANG A ET AL: "Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability.", CANCER RESEARCH 57 (21). 1997. 4876-4881. ISSN: 0008-5472, XP002053166 *
L. THELANDER ET AL.: "Isolation and characterization of expressible cDNA clones encoding the M1 and M2 subunits of mouse ribonucleotide reductase.", MOLECULAR AND CELLULAR BIOLOGY, vol. 6, no. 10, October 1986 (1986-10-01), pages 3433 - 3442, XP002053157 *
M. THELANDER ET AL.: "Molecular cloning and expression of the functional gene encoding the M2 subunit of mouse ribonucleotide reductase: a new dominant marker gene.", THE EMBO JOURNAL, vol. 8, no. 9, 1989, pages 2475 - 2479, XP002053158 *
M.M. CHAUDHURI ET AL.: "cDNA sequence of the small subunit of the hamster ribonucleotide reductase.", BIOCHEMICA ET BIOPHYSICA ACTA, vol. 1171, 1992, pages 117 - 121, XP002053159 *
MADER R M ET AL: "Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidine resistance in colon cancer in vitro.", BIOCHEMICAL PHARMACOLOGY 54 (11). 1997. 1233-1242. ISSN: 0006-2952, XP002053167 *
N. PAVLOFF ET AL.: "Sequence analysis of the large and small subunits of human ribonucleotide reductase.", DNA SEQUENCE, vol. 2, 1992, pages 227 - 234, XP002048232 *
R.A.R. HURTA ET AL.: "Early induction of ribonucleotide reductase gene expression by transforming growth factor beta1 in malignant H-ras transformed cell lines.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 35, 15 December 1991 (1991-12-15), pages 24097 - 24100, XP002053309 *
STANDARD N ET AL: "MATERNAL MESSENGER RNA FROM CLAM OOCYTES CAN BE SPECIFICALLY UNMASKED IN-VITRO BY ANTISENSE RNA COMPLEMENTARY TO THE 3'-UNTRANSLATED REGION.", GENES DEV 4 (12A). 1990. 2157-2168. CODEN: GEDEEP ISSN: 0890-9369, XP002053164 *
STANDART N ET AL: "CONTROL OF TRANSLATION OF MASKED MRNAS IN CLAM OOCYTES.", ENZYME (BASEL) 44 (1-4). 1990 (1991). 106-119. CODEN: ENZYBT ISSN: 0013-9432, XP002053165 *

Also Published As

Publication number Publication date
US5998383A (en) 1999-12-07
IL128124A0 (en) 1999-11-30
IL128124A (en) 2006-12-31
CA2262776A1 (en) 1998-02-12
CN1231694A (en) 1999-10-13
JP2000517167A (en) 2000-12-26
AU738592B2 (en) 2001-09-20
ES2256893T3 (en) 2006-07-16
DE69734589D1 (en) 2005-12-15
NZ333802A (en) 2001-09-28
AU3617597A (en) 1998-02-25
AU738592C (en) 2002-07-25
JP4301576B2 (en) 2009-07-22
CN1189562C (en) 2005-02-16
DE69734589T2 (en) 2006-08-10
EP0917569A2 (en) 1999-05-26
ATE309345T1 (en) 2005-11-15
EP0917569B1 (en) 2005-11-09
CA2262776C (en) 2005-03-08
WO1998005769A2 (en) 1998-02-12

Similar Documents

Publication Publication Date Title
WO1998005769A3 (en) Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
MXPA01008137A (en) Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase.
AU7585598A (en) Raf kinase inhibitors
WO1998000532A3 (en) Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth
WO2000071703A3 (en) Inhibition of histone deacetylase
EP0981607A4 (en) Modiified arginine deiminase
GR20010300007T1 (en) Inhibition of raf kinase using substituted heterocyclic ureas
ZA9810332B (en) Aminothiazone inhibitors of cyclin dependent kinases.
WO2001038532A3 (en) Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
WO2002036743A3 (en) Antisense modulation of calreticulin expression
AU2001248701A1 (en) Inhibitors of histone deacetylase
GB9927444D0 (en) Inhibiting gene expression
MY136037A (en) Biphenyl pyrimidone lp-pla2 inhibitors
PT1117672E (en) Antisense modulation of survivin expression
WO1996035784A3 (en) Chromatin-regulator genes
WO2003048315A3 (en) Antisense modulation of mdm2 expression
ZA983608B (en) Leptin as an inhibitor of tumor cell proliferation
AU3307999A (en) Phosphodiesterase 10
WO1999002673A3 (en) Antisense oligonucleotide sequences as inhibitors of microorganisms
AU1329700A (en) Method of interfering with cell proliferation
WO2003028636A3 (en) Antisense modulation of il-1 receptor-associated kinase-4 expression
AU2606000A (en) Antisense modulation of x-linked inhibitor of apoptosis expression
AU4068999A (en) Optimized nucleotide sequence encoding organophosphorous hydrolase and methods of use for same
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
AU1759901A (en) Compositions and methods for regulating endogenous inhibitor of atp synthase, including treatment for diabetes

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97198163.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD GH

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

WWE Wipo information: entry into national phase

Ref document number: 333802

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 09230521

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2262776

Country of ref document: CA

Ref document number: 2262776

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997932690

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997932690

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1997932690

Country of ref document: EP